M STO THE Order Ofcamber Pharmaceuticals Inc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: M STO THE Order Ofcamber Pharmaceuticals Inc Pharmaceutical Import Records from India — 2 Products, $340.8K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

M STO THE Order Ofcamber Pharmaceuticals Inc — Pharmaceutical Importer Profile (2026) | 2 Products, $340.8K Trade | TransData Nexus

M STO THE Order Ofcamber Pharmaceuticals Inc

Pharmaceutical Importer · United States · Lipid & Metabolism Focus · $340.8K Total Trade · DGFT Verified

M STO THE Order Ofcamber Pharmaceuticals Inc is a pharmaceutical importer based in United States with a total trade value of $340.8K across 2 products in 2 therapeutic categories. Based on 11 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. M STO THE Order Ofcamber Pharmaceuticals Inc sources from 2 verified Indian suppliers, with Annora Pharma Private Limited accounting for 69.6% of imports.

M STO THE Order Ofcamber Pharmaceuticals Inc — Import Portfolio & Supplier Network

M STO THE Order Ofcamber Pharmaceuticals Inc import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to M STO THE Order Ofcamber Pharmaceuticals Inc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Annora Pharma Private Limited	$4.5M	117	69.6%
Hetero Labs Limited	$2.0M	55	30.4%

M STO THE Order Ofcamber Pharmaceuticals Inc sources from across .

What Formulations Does M STO THE Order Ofcamber Pharmaceuticals Inc Import?

Formulation	Value	Ships
Droxidopa 300MG caps1320 packs of 90	$200.0K	4
Oxcarbazepine	$150.0K	3
Venlafax. hcl er cap venlafaxine hydrochloride CAPS	$142.6K	3
Dabigatran etexilate mesylate 150 CAPS qty in 4704282240 CAPS Pack of 60	$100.0K	2
Levetiracetam 250MG tabs3444 packs of 500 s1722000 tabs unit price 16	$100.0K	2
Sildenafil citrate 100MG tabs 9696x100's	$100.0K	2
Finasteride 1 MG tabs qty in 62424 1872720 tabs Pack of 30	$100.0K	2
Diclofenac potassium	$100.0K	2
Sildenafil citrate	$99.0K	4
Hydralazine hcl	$95.7K	2
Droxidopa 100MG caps1152 packs of 90	$80.0K	2
Hydralazine hcl 100 MG tabs Pack of 100nos1180800	$69.8K	2
Levetiracetam oral solution 100MG/mllevetiracetam 100MG/ML solution 8010 Pack 1s	$68.7K	2
Levetiracetam 750MG tabs 9744 packs x 7.35 usd1169280	$50.0K	1
Levetiracetam 750MG tabs 35280 packs x7.35 usd4233600	$50.0K	1

M STO THE Order Ofcamber Pharmaceuticals Inc imports 148 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Colchicine	Lipid & Metabolism	$190.8K	8	0.9%	13
2	Atovaquone	Antimalarial & Antiparasitic	$150.0K	3	0.0%	12

M STO THE Order Ofcamber Pharmaceuticals Inc imports 2 pharmaceutical products across 2 categories into United States totaling $340.8K.

M STO THE Order Ofcamber Pharmaceuticals Inc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

M STO THE Order Ofcamber Pharmaceuticals Inc is a pharmaceutical importer based in the United States, specializing in the acquisition of finished pharmaceutical formulations from international suppliers. The company operates as a buyer, sourcing a range of pharmaceutical products to meet domestic market demands. While specific details about its headquarters and parent company are not publicly disclosed, its role in the U.S. pharmaceutical distribution network is significant, focusing on importing and distributing finished dosage forms such as tablets, capsules, syrups, and injections.

2Distribution Network

The distribution network of M STO THE Order Ofcamber Pharmaceuticals Inc encompasses multiple warehouse locations across the United States, strategically positioned to ensure efficient logistics and timely delivery of pharmaceutical products. The company's logistics capabilities are robust, facilitating nationwide coverage and enabling prompt distribution to various healthcare providers, including hospitals, pharmacies, and clinics. While specific details about international distribution are not publicly available, the company's import activities suggest a focus on the U.S. market.

3Industry Role

In the U.S. pharmaceutical supply chain, M STO THE Order Ofcamber Pharmaceuticals Inc functions primarily as a pharmaceutical importer and distributor. By sourcing finished pharmaceutical formulations from international suppliers, the company plays a crucial role in ensuring the availability of a diverse range of medications to meet domestic healthcare needs. Its operations support the broader distribution network, contributing to the accessibility and affordability of pharmaceutical products across the United States.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — M STO THE Order Ofcamber Pharmaceuticals Inc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

M STO THE Order Ofcamber Pharmaceuticals Inc demonstrates a high degree of supplier concentration, with 69.6% of its imports sourced from ANNORA PHARMA PRIVATE LIMITED and 30.4% from HETERO LABS LIMITED. This significant reliance on two suppliers indicates a strategic choice to maintain strong, stable relationships with key partners. However, such concentration also presents potential risks, including supply chain disruptions due to geopolitical events, regulatory changes, or operational challenges faced by these suppliers. The company's consistent import activity over 11 shipments suggests a stable and ongoing relationship with these suppliers, which may mitigate some risks associated with supplier concentration.

2Supply Chain Resilience

The resilience of M STO THE Order Ofcamber Pharmaceuticals Inc's supply chain is closely tied to the stability and reliability of its primary suppliers, ANNORA PHARMA PRIVATE LIMITED and HETERO LABS LIMITED. Both suppliers are established entities in the pharmaceutical industry, likely adhering to Good Manufacturing Practices (GMP) and other regulatory standards. However, the company's limited supplier base may expose it to risks if these suppliers encounter production issues, regulatory challenges, or other disruptions. Diversifying the supplier base and establishing relationships with additional manufacturers could enhance supply chain resilience and mitigate potential risks.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The FDA enforces the Federal Food, Drug, and Cosmetic Act (FD&C Act), which sets forth requirements for drug safety, efficacy, and quality. Pharmaceutical imports must comply with FDA regulations, including registration of foreign manufacturing facilities, listing of drug products, and adherence to Good Manufacturing Practices (GMP). The FDA's oversight ensures that imported drugs meet the same standards as domestically produced products, safeguarding public health.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the United States are stringent. Foreign manufacturers must register their establishments with the FDA and list all drug products intended for import. Compliance with GMP is mandatory, ensuring that manufacturing processes meet FDA standards for quality and safety. Recognized certifications such as EU GMP, WHO GMP, and PIC/S are acceptable, provided they align with FDA requirements. Additionally, importers must obtain wholesale distribution authorization to legally distribute pharmaceutical products within the U.S.

Quality & Labeling

M STO THE Order Ofcamber Pharmaceuticals Inc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

M STO THE Order Ofcamber Pharmaceuticals Inc's focus on importing products in the Lipid & Metabolism and Antimalarial & Antiparasitic therapeutic categories suggests a strategic alignment with prevalent health concerns and market demands in the United States. The significant import value of Colchicine and Atovaquone indicates a targeted approach to address specific medical conditions, such as gout and malaria, respectively. This product strategy reflects the company's commitment to providing essential medications that meet critical healthcare needs.

2Sourcing Profile

The company's sourcing strategy emphasizes the procurement of generic drug formulations, primarily from India, a major global supplier of affordable pharmaceuticals. By focusing on finished dosage forms, M STO THE Order Ofcamber Pharmaceuticals Inc ensures that imported products are ready for distribution, aligning with the FDA's requirements for drug imports. This approach allows the company to offer a diverse range of medications while maintaining compliance with regulatory standards.

3Market Positioning

Based on its product mix, M STO THE Order Ofcamber Pharmaceuticals Inc serves the wholesale distribution segment of the U.S. pharmaceutical market. By importing and distributing finished pharmaceutical formulations, the company supplies medications to various healthcare providers, including hospitals, pharmacies, and clinics, thereby contributing to the overall healthcare infrastructure.

Seller's Guide — How to Become a Supplier to M STO THE Order Ofcamber Pharmaceuticals Inc

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with M STO THE Order Ofcamber Pharmaceuticals Inc, particularly those offering products that complement the company's existing portfolio or provide alternative formulations. Expanding the supplier base could enhance the company's product offerings and mitigate risks associated with supplier concentration. For Indian exporters, establishing relationships with the company could open avenues for market entry into the U.S., leveraging the existing distribution network and regulatory compliance frameworks.

2Requirements & Qualifications

Indian exporters seeking to supply M STO THE Order Ofcamber Pharmaceuticals Inc must ensure that their products comply with FDA regulations, including registration of manufacturing facilities, listing of drug products, and adherence to GMP standards. Certifications such as EU GMP, WHO GMP, and PIC/S are recognized, provided they align with FDA requirements. Additionally, products must meet FDA labeling requirements, including English language labeling and inclusion of all necessary information.

3How to Approach

Frequently Asked Questions — M STO THE Order Ofcamber Pharmaceuticals Inc

What products does M STO THE Order Ofcamber Pharmaceuticals Inc import from India?

M STO THE Order Ofcamber Pharmaceuticals Inc imports 2 pharmaceutical products across 2 categories. Top imports: Colchicine ($190.8K), Atovaquone ($150.0K).

Who supplies pharmaceuticals to M STO THE Order Ofcamber Pharmaceuticals Inc from India?

M STO THE Order Ofcamber Pharmaceuticals Inc sources from 2 verified Indian suppliers. The primary supplier is Annora Pharma Private Limited (69.6% of imports, $4.5M).

What is M STO THE Order Ofcamber Pharmaceuticals Inc's total pharmaceutical import value?

M STO THE Order Ofcamber Pharmaceuticals Inc's total pharmaceutical import value from India is $340.8K, based on 11 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does M STO THE Order Ofcamber Pharmaceuticals Inc focus on?

M STO THE Order Ofcamber Pharmaceuticals Inc imports across 2 categories. The largest: Lipid & Metabolism (56.0%), Antimalarial & Antiparasitic (44.0%).

Get Full M STO THE Order Ofcamber Pharmaceuticals Inc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.